Skip to main content


A phase 1/1b clinical trial for patients with KRAS mutant, unresectable, locally advanced and/ metastatic NSCLC, PDAC, and CRC.

About COVALENT-102

What is the NCT number for COVALENT-102?

The National Clinical Trial reference number is: NCT05631574

When you talk with your doctor or clinical trial team member, please have the national trial reference number available.

What does it mean it is open label, non-randomized?

It means all patients will receive the BMF-219, the study drug and that the dose level will be pre-allocated. There will be no placebo and the allocation will not be based on chance.

Will it cost me anything?

Study medication and study-related care will be provided at no cost.

Patient eligibility

18 years & over
Female & Male
Solid Tumors
  • Be 18 years of age or older
  • All sexes included

Have either:

  • NSCLC and at least 2 but no more than 4 previous treatments, or
  • Pancreatic cancer and have received at least one previous treatment, or
  • CRC and have received at least one previous treatment

And also:

  • Have any type of KRAS mutation in their cancer
  • Have not had success with standard of care treatments
  • Had cancer come back or get worse after getting better

The science behind COVALENT-102

What is BMF-219?

BMF-219 is an investigational, orally bioavailable small molecule, which covalently binds to the scaffold protein menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. 

Contact us

Our clinical trials team will contact you shortly after your form submission.